Antioxidants

Antioxidants are the second-oldest hallmark-of-aging story in biogerontology — Denham Harman's 1956 free-radical theory predates the modern Hallmarks framework by nearly 60 years — but the way antioxidants extend healthspan was rewritten three times between 1995 and 2023. The original "more is better" model — mega-dose vitamin E, mega-dose β-carotene, mop up every radical — was falsified by SELECT (2011), CARET (1996), and ATBC (1994). What replaced it: the antioxidant network (Packer 1995), the Nrf2-Keap1 endogenous defense axis (Itoh 1997), redox signaling versus oxidative damage (Sies 2017), and the recognition that mitochondrial ROS is upstream of half the López-Otín 2013/2023 hallmarks (mitochondrial dysfunction, cellular senescence/SASP, inflammaging, loss of proteostasis, deregulated nutrient sensing).

This collection is built around that modern picture. 11 SKUs across 4 functional categories — Nrf2 activators (Curcumin 1000mg + BioPerine, Resveratrol 600mg, Pterostilbene 100mg), direct membrane and aqueous antioxidants (Astaxanthin 12mg, CoQ10 400mg, Liposomal Vitamin C 1000mg, ALA 600mg as the universal-network recycler), the glutathione axis (Glutathione 500mg enteric-coated reduced GSH, NAC 600mg as the cysteine donor), and the NAD+/sirtuin-coupled formulas (Liposomal NAD+ Ultimate 1000mg, NAD+ 5-in-1 Complete) — each cGMP-manufactured, USP- or pharmaceutical-grade, HPLC-verified for the relevant fingerprints (≥95% curcuminoids, ≥98% trans-resveratrol, ≥97% trans-pterostilbene, R/S-α-lipoic acid identity, natural Haematococcus pluvialis astaxanthin, reduced-GSH versus oxidized GSSG, ascorbic-acid + phospholipid encapsulation efficiency, β-NMN purity), ICP-MS heavy-metal screened, free of titanium dioxide, proprietary blends, and excipient bloat.

This page is the canonical reference for assembling an antioxidant program that survives modern critique. It covers the four-category Packer network, the Nrf2-Keap1 endogenous-defense pathway, the glutathione cycle and why oral GSH versus NAC is not a settled question, the membrane-versus-aqueous compartment problem (and why astaxanthin's polar-nonpolar-polar structure is unique), the mitochondrial-ROS hypothesis (Harman 1972, Cadenas & Davies 2000), why exercise-induced ROS is a signal not damage (Ristow 2009), the antioxidant-and-chemotherapy debate, why "ORAC score" was withdrawn by the USDA in 2012, and the per-SKU dosing logic anchored to the trials that moved a clinical endpoint.

The 60-second answer — what to take, when

If you only have a minute, this is the decision tree. Each branch maps to a real clinical or longevity-research endpoint, with the trial that grounded it.

• This collection covers 11 SKUs across the 4 Packer-network categories (Nrf2 activators, membrane/aqueous antioxidants, glutathione axis, NAD+/sirtuin-coupled formulas) — every category protected by pathway redundancy.
• Pick Curcumin 1000mg + BioPerine if your goal is anti-inflammatory longevity — Nrf2 induction (Balogun 2003, Biochem J), NF-κB suppression (Aggarwal 2007, Adv Exp Med Biol), CRP reduction in meta-analysis (Sahebkar 2014, Phytother Res); BioPerine 5mg raises systemic curcumin exposure ~20× (Shoba 1998, Planta Medica).
• Pick Resveratrol 600mg if you want SIRT1 activation paired with antioxidant + Nrf2 effects — substrate-specific SIRT1 deacetylation (Howitz 2003 Nature; Hubbard 2013 Science resolved the 2010-era allosteric controversy), 30-day ¹H-MRS-confirmed metabolic shift in obese men (Timmers 2011, Cell Metab), and dual Nrf2/SIRT1 transcriptional activation (Kulkarni 2015, Antioxid Redox Signal).
• Pick Pterostilbene 100mg if you tolerated resveratrol but want the methylated, more bioavailable cousin — 4× longer plasma half-life (~105 min vs ~14 min for resveratrol; Kapetanovic 2011, Cancer Chemother Pharmacol), parallel SIRT1 activation, and the lipid-modulating signal in McCormack 2013 (J Med Food).
• Pick Alpha-Lipoic Acid 600mg if mitochondria, glucose, or peripheral nerves need help — the only "universal" antioxidant (lipid + aqueous; Packer 1995, Free Radic Biol Med), regenerates vitamin C and vitamin E, supports diabetic peripheral neuropathy (Ziegler 2011 NATHAN-1, 4-yr Diabetes Care; Ametov 2003 SYDNEY-2 dose-response, Diabetes Care), and is the dihydrolipoamide cofactor of pyruvate-dehydrogenase + α-ketoglutarate-dehydrogenase (Reed 2001, J Biol Chem).
• Pick Astaxanthin 12mg if your priority is membranes, skin, or eyes — natural-source Haematococcus, polar-nonpolar-polar (PNP) structure spans the lipid bilayer (Goto 2001, Biochim Biophys Acta), 12-week skin-elasticity trial (Tominaga 2012, Acta Biochim Pol), macular pigment optical density signal (Hashimoto 2014, J Clin Biochem Nutr), and the only carotenoid that does not act as a pro-oxidant at high concentrations (Beutner 2001, Mol Aspects Med).
• Pick CoQ10 400mg if your priority is mitochondrial energetics, statin-related myalgia, or cardiac output — Q-Symbio 2014 (JACC Heart Fail) NYHA III/IV heart-failure mortality reduction, Caso 2007 (Am J Cardiol) statin-myopathy CK reduction, Olson 1989 / Tran 2001 ubiquinone biosynthesis review.
• Pick Glutathione 500mg (enteric-coated, reduced GSH) if your priority is liver, skin tone, or detoxification capacity — Richie 2015 (Eur J Nutr) 6-month oral GSH trial showed RBC + plasma + lymphocyte GSH increase; enteric coating bypasses gastric γ-glutamyl-transpeptidase cleavage and is the modern delivery answer to the Witschi 1992 (Eur J Clin Pharmacol) bioavailability problem.
• Pick NAC 600mg if you want the rate-limiting cysteine donor for endogenous GSH synthesis — paracetamol-overdose antidote (Smilkstein 1988, NEJM), MARCO 2014 chronic bronchitis trial (Chest), pulmonary-fibrosis exploratory data (Demedts 2005 IFIGENIA, NEJM), and a 50-year regulatory safety record at gram doses.
• Pick Liposomal Vitamin C 1000mg if you want pharmacologic plasma vitamin C without IV — phospholipid encapsulation roughly doubles plasma AUC versus equivalent ascorbic-acid tablets (Davis 2016 Nutr Metab Insights), and the prolyl/lysyl-hydroxylase cofactor role anchors collagen-stabilization endpoints (Carr 2017 Nutrients).
• Pick Liposomal NAD+ Ultimate 1000mg or NAD+ 5-in-1 Complete if you want NAD+ precursor + antioxidant cofactors stacked — covers the SIRT3 mitochondrial deacetylation axis (Hirschey 2010 Nature), with parallel B-complex and antioxidant cofactors (riboflavin/FAD, niacinamide, B6, B12, methylfolate) supporting one-carbon and redox metabolism.
• Time-to-effect window: 1–2 weeks for HMOX1 transcriptional Nrf2 markers (Liu 2009 Cell Mol Biol Lett); 4–6 weeks for plasma GSH on oral reduced-glutathione (Richie 2015); 8–12 weeks for skin-elasticity / corneocyte-water on astaxanthin (Tominaga 2012); 12 weeks for fasted-glucose / HbA1c with the metabolic stack (Lan 2015 berberine + ALA meta-analyses); 24+ weeks for the Q-Symbio mortality endpoint (Mortensen 2014).
• Quality bar: cGMP, USP- or pharmacopoeia-grade actives, HPLC-verified fingerprints, ICP-MS heavy-metal panel, no titanium dioxide, no proprietary blends, no magnesium-stearate excipient bloat.

On-page contents

1. Why this collection exists — oxidative stress as a hallmark of aging, and why "antioxidant" was redefined twice
2. The 5-step qualification filter — what we will not stock and why
3. The 6-step decision tree — pick a category and a SKU in 60 seconds
4. Mechanism backbone — antioxidants and 5 of the 12 Hallmarks of Aging
5. The Packer network — 4 compartments, 11 SKUs, primary references
6. Per-SKU evidence — Curcumin 1000mg + BioPerine
7. Per-SKU evidence — Resveratrol 600mg
8. Per-SKU evidence — Pterostilbene 100mg
9. Per-SKU evidence — Alpha-Lipoic Acid 600mg
10. Per-SKU evidence — Astaxanthin 12mg natural Haematococcus
11. Per-SKU evidence — CoQ10 400mg
12. Per-SKU evidence — Glutathione 500mg enteric-coated reduced GSH
13. Per-SKU evidence — N-Acetyl Cysteine 600mg
14. Per-SKU evidence — Liposomal Vitamin C 1000mg
15. Per-SKU evidence — Liposomal NAD+ Ultimate 1000mg + NAD+ 5-in-1 Complete
16. Stacking protocols — 5 reference protocols
17. Time-to-effect timeline (week-by-week)
18. What to avoid — the 6 antioxidant mistakes
19. Frequently asked antioxidant questions
20. Selected references (37 citations)

Why this collection exists — oxidative stress as a hallmark of aging, and why "antioxidant" was redefined twice

The first version of the free-radical theory of aging is Denham Harman's 1956 paper in the Journal of Gerontology ("Aging: a theory based on free radical and radiation chemistry"). The 1956 framing was simple: free radicals damage macromolecules, damage accumulates, that is aging. Harman extended it in 1972 (Journal of the American Geriatrics Society) to the mitochondrial free-radical theory — placing the electron-transport chain (specifically Complex I and Complex III) as the dominant intracellular ROS source and proposing that mitochondrial damage is the rate-limiting layer of aging.

That framing has held — with revisions. Cadenas & Davies (2000, Free Radical Biology and Medicine) consolidated the biochemistry: Complex I leaks O₂•⁻ into the matrix, Complex III leaks both into the matrix and the inter-membrane space, and the total mitochondrial ROS output scales with membrane potential (ΔΨm) and the NADH/NAD+ ratio. López-Otín 2013 (Cell) listed mitochondrial dysfunction as one of the 9 original Hallmarks; the 2023 update kept it (now Hallmark 4 of 12) and added chronic inflammation/inflammaging and compromised autophagy as Hallmarks 11 and 12 — both downstream of redox imbalance.

The supplement-aisle picture lagged. Through the 1980s and 1990s the dominant model was "antioxidant deficiency causes disease, mega-dose to fix it." Three landmark trials buried that:

• ATBC (1994, NEJM) — Finnish Alpha-Tocopherol Beta-Carotene Cancer Prevention Study, 29,133 male smokers — high-dose β-carotene increased lung cancer 18%, all-cause mortality 8%.
• CARET (1996, NEJM) — β-carotene + retinol in 18,314 smokers + asbestos workers — stopped 21 months early for harm; 28% increase in lung cancer.
• SELECT (2011, JAMA) — Selenium and Vitamin E Cancer Prevention Trial, 35,533 men — vitamin E 400 IU/d increased prostate cancer risk 17% over 7 years.

What replaced "mega-dose any antioxidant" is the modern picture, which has four pillars:

1. The antioxidant network (Packer 1995, Free Radical Biology and Medicine). Antioxidants do not act independently — they regenerate each other. Vitamin E (α-tocopherol) at the membrane is recycled by ascorbate; ascorbate is recycled by reduced glutathione (GSH); GSH is recycled by NADPH via glutathione reductase; NADPH is generated by the pentose-phosphate pathway. Alpha-lipoic acid is "universal" because the lipoate/dihydrolipoate redox couple regenerates all of the above (Packer 1995). This is why mega-dosing one compound fails: the network is rate-limited by the recycling step, not the absolute concentration of any single antioxidant.
2. Nrf2-Keap1 (Itoh 1997, Biochem Biophys Res Commun; Tonelli 2018, Antioxid Redox Signal). Endogenous antioxidant defense is transcriptionally regulated. Nrf2 (NF-E2-related factor 2) binds the antioxidant-response element (ARE) in the promoter of HMOX1 (heme oxygenase-1), NQO1 (NAD(P)H quinone dehydrogenase 1), GCLC (glutamate-cysteine ligase, the rate-limiting GSH-synthesis enzyme), GCLM, GSR (glutathione reductase), and TXN (thioredoxin). Pharmacologically activating Nrf2 raises endogenous antioxidant capacity, which is more durable than mass-action mopping. Curcumin (Balogun 2003), resveratrol (Kulkarni 2015), pterostilbene (Park 2017), and α-lipoic acid (Suh 2004) are all Nrf2 inducers — the "phytochemical hormesis" axis.
3. Redox signaling versus oxidative damage (Sies 2017, Redox Biology; "oxidative eustress"). Low-level H₂O₂ is a signaling molecule. Insulin signaling uses H₂O₂ to oxidize PTP1B at Cys-215, prolonging the insulin-receptor phosphotyrosine signal (Mahadev 2001, J Biol Chem). Exercise-induced ROS triggers the PGC-1α / mitochondrial-biogenesis response (Ristow 2009 PNAS — and Ristow famously showed antioxidant supplementation blunts the insulin-sensitizing effect of exercise). The modern goal is not to abolish ROS — it is to keep oxidative distress down (chronic, damaging, network-overwhelming) while preserving oxidative eustress (transient, signaling, network-buffered).
4. Mitochondrial compartment dominance. Cadenas & Davies 2000, Wallace 2010 (Annu Rev Genet), and Sun 2016 (Cell) converge on the same picture — the mitochondrial matrix is where ROS damage matters most for aging, because mtDNA has no protective histones, mtDNA replication is asymmetric, and damaged mitochondria are cleared only via mitophagy (Lemasters 2005). Antioxidants that reach the matrix (CoQ10's ubiquinol form, MitoQ, the matrix-targeted SkQ1) carry more leverage per molecule than aqueous-phase antioxidants. This is why CoQ10 + α-lipoic acid + astaxanthin (membrane-spanning) sit at the top of the matrix-protective ladder.

The collection is built around all four pillars. Network coverage is provided by ALA + glutathione + ascorbate. Nrf2 induction is provided by curcumin + resveratrol + pterostilbene + ALA. Membrane / matrix coverage is provided by CoQ10 + astaxanthin + the NAD+ precursors (which feed SIRT3 in the matrix). Glutathione axis is provided directly (reduced GSH enteric-coated) and indirectly (NAC as the cysteine-rate-limiting precursor). The modern picture is "redundancy across compartments and pathways" — not "stack the dose of one."

The 5-step qualification filter — what we will not stock and why

Every SKU on this page passes a 5-step filter. We document the filter so you can audit it.

1. Trial-anchored dose. Whatever dose is on the label has to map to a published clinical or peer-reviewed mechanistic trial. Curcumin 1000mg + BioPerine 5mg is the Sahebkar 2014 / Hewlings 2017 (Foods) range; resveratrol 600mg is the upper edge of the Timmers 2011 metabolic-shift dose; ALA 600mg is the Ziegler 2011 NATHAN-1 / Ametov 2003 SYDNEY-2 dose; astaxanthin 12mg is the Tominaga 2012 skin-elasticity dose; CoQ10 400mg is the Q-Symbio 300mg ÷ Mortensen scaled into the upper-clinical zone; reduced GSH 500mg is the Richie 2015 oral arm; NAC 600mg is the MARCO 2014 chronic bronchitis dose; vitamin C 1000mg liposomal is the Davis 2016 plasma-AUC dose; β-NMN 500mg / 1000mg is the Yoshino 2021 / Pencina 2023 / Igarashi 2022 trial range. We don't do "fairy dust" doses.
2. Mechanism completeness when paired. If a compound has a known cofactor that gates absorption or activation, the cofactor is in the formula or the protocol calls for it. Curcumin without piperine is poorly bioavailable — so BioPerine 5mg is in the formula (Shoba 1998). NAC and oral GSH both feed the GSH cycle but at different points — the protocol specifies which to take when. Liposomal vitamin C requires a phospholipid carrier (sunflower-derived phosphatidylcholine) — so we use that. Resveratrol works better with mild meal-timing fat, ALA works better fasted — and we tell you that.
3. Independent purity verification. ≥95% curcuminoids by HPLC for the curcumin SKU, ≥98% trans-resveratrol (not trans+cis nor "Polygonum cuspidatum extract" with unclear emodin contamination), ≥97% trans-pterostilbene, R/S-α-lipoic acid identity confirmed, β-NMN purity for the NAD+ SKUs, reduced GSH versus oxidized GSSG ratio specified for the GSH SKU, natural-source astaxanthin from Haematococcus pluvialis (not synthetic Phaffia-rhodozyma-style which has lower 3S,3'S all-trans content), USP-grade ascorbic acid for the vitamin C SKU. Heavy-metal screening by ICP-MS to USP <232> / <233> thresholds (Pb, Cd, As, Hg).
4. Manufacturing quality. cGMP-registered facilities, no titanium dioxide (banned EFSA 2022 as a food additive), no magnesium-stearate excipient bloat, no proprietary blends (every active is dose-disclosed on the label), no synthetic dyes, vegetarian capsules where the compound allows.
5. Risk asymmetry. Each SKU has a documented safety record at the trial dose. ALA at 600mg has the 4-year NATHAN-1 follow-up; CoQ10 has the Q-Symbio 2-year follow-up; NAC has 50+ years as an N-acetylcysteine pharmaceutical; astaxanthin has the Spiller 2003 8-week safety dossier; oral GSH has the Richie 2015 6-month follow-up; pterostilbene has the Riche 2014 12-week safety run. Where a compound has a known interaction (warfarin + curcumin/CoQ10, chemotherapy + any antioxidant) we surface it in the FAQ and the per-SKU detail.

The 6-step decision tree — pick a category and a SKU in 60 seconds

1. If your dominant goal is anti-inflammatory longevity (high CRP, joint stiffness, low-grade systemic inflammation) → start with Curcumin 1000mg + BioPerine. Stack with omega-3 if available. Anchored in Sahebkar 2014 (CRP meta-analysis) and the AMPK/NF-κB suppression axis. Add Resveratrol 600mg if you also want SIRT1 activation. Time-to-effect: 6–8 weeks for hsCRP movement.
2. If your dominant goal is mitochondrial energy + glucose metabolism → start with Alpha-Lipoic Acid 600mg + CoQ10 400mg. ALA covers the universal-network role + glucose/AMPK; CoQ10 covers ETC Complex II→III electron transfer + statin myopathy. Add Berberine 500mg (from the Metabolic collection) if fasting glucose > 100 or HbA1c > 5.6. Time-to-effect: 6–12 weeks.
3. If your dominant goal is skin, eyes, membranes, or cosmetic outcomes → start with Astaxanthin 12mg + Liposomal Vitamin C 1000mg + Multi Collagen Complex (from the Collagen collection). Astaxanthin spans the membrane (PNP polar-nonpolar-polar), vitamin C is the hydroxylase cofactor for procollagen, and collagen peptides supply the substrate. Time-to-effect: 8–12 weeks for elasticity / corneocyte hydration.
4. If your dominant goal is liver / detoxification / hangover / chronic exposure → start with NAC 600mg + Glutathione 500mg (enteric-coated reduced GSH). NAC is the GSH precursor; oral GSH is direct supplementation. Pair with milk-thistle-derived silymarin if liver-enzyme-elevation is the trigger. Time-to-effect: 4–6 weeks for plasma GSH.
5. If your dominant goal is NAD+ + mitochondrial-renewal + sirtuin-activation → start with Liposomal NAD+ Ultimate 1000mg or NAD+ 5-in-1 Complete + Resveratrol 600mg. The NAD+ axis powers SIRT1 (nuclear) + SIRT3 (mitochondrial); resveratrol is the substrate-specific SIRT1 activator. The Liposomal NAD+ formula adds CoQ10 + B-complex cofactors; the 5-in-1 adds skin-targeted cofactors. See the NAD+ Family collection for in-depth NAD+ guidance.
6. If you want a "cover everything" antioxidant program (Comprehensive stack) → Curcumin 1000mg + Resveratrol 600mg + ALA 600mg + Astaxanthin 12mg + CoQ10 400mg + NAC 600mg, with optional Glutathione 500mg + Liposomal Vitamin C 1000mg. This is the full Packer-network coverage across all four compartments + Nrf2 + GSH cycle + mitochondrial matrix + membranes + aqueous phase. Time-to-effect: 4–12 weeks depending on the endpoint. See the Comprehensive stack section below for the full timing table.

Mechanism backbone — antioxidants and 5 of the 12 Hallmarks of Aging

The López-Otín 2013/2023 Hallmarks of Aging framework is the dominant biogerontology synthesis. Here is how this collection maps to 5 of the 12 hallmarks. (Hallmarks 6, 7, 8, 9 — telomere attrition, epigenetic alteration, stem-cell exhaustion, altered intercellular communication — are addressed in the NAD+ Family, Senolytics, and NMN collections.)

Hallmark 4 — Mitochondrial dysfunction

The mitochondrial free-radical theory (Harman 1972, Cadenas & Davies 2000) places the matrix and the inner membrane as the dominant ROS-leak sites. Coverage in this collection: CoQ10 400mg (Complex II→III electron-transfer cofactor; ubiquinone/ubiquinol redox couple; Olson 1989, Mortensen 2014 Q-Symbio); Alpha-Lipoic Acid 600mg (PDH + KGDH cofactor — Reed 2001; mitochondrial biogenesis signal in old rats — Hagen 2002 FASEB J; SIRT3-coupled in Suh 2003 FASEB J); Astaxanthin 12mg (membrane-spanning; reduces mitochondrial ROS in cardiomyocyte models — Wolf 2010 Am J Physiol); NAD+ precursors (Liposomal NAD+ Ultimate, NAD+ 5-in-1, plus the entry-tier Pure NMN 500mg from the NMN collection — feeding SIRT3 deacetylation of MnSOD K68 — Qiu 2010 Cell Metab; Tao 2010 Mol Cell).

Hallmark 5 — Cellular senescence / SASP

Senescent cells secrete pro-inflammatory IL-6, IL-8, MMPs (the Senescence-Associated Secretory Phenotype, Coppé 2008 PLoS Biol; Tchkonia 2013 J Clin Invest). Oxidative stress accelerates senescence (Chen 1995 Exp Cell Res); antioxidants attenuate it. Coverage in this collection: Curcumin (suppresses NF-κB and SASP cytokines — Aggarwal 2007), Resveratrol (Manna 2000 NF-κB, J Immunol; SIRT1-mediated p53 deacetylation in Vaziri 2001 Cell), Pterostilbene (parallel SIRT1 activation, Park 2017 review), NAC (suppresses TNFα-induced senescence in vitro, Petrache 2003 Lab Invest), and Astaxanthin (suppresses senescence-associated β-galactosidase signal in fibroblast aging models, Yang 2017 Mar Drugs).

Hallmark 8 — Loss of proteostasis / autophagy

Proteostasis depends on three buffer layers: chaperones (HSP70, HSP90), the ubiquitin-proteasome system, and autophagy/lysosomes (Mizushima 2008 Nature). Oxidatively damaged proteins overwhelm proteasome capacity (Davies 2001 Biochimie); autophagy is required for protein-aggregate clearance and is regulated by AMPK (Egan 2011 Science) and mTOR (Russell 2014 Nat Rev Mol Cell Biol). Coverage: Resveratrol (Morselli 2010 Aging — induces LC3-II + ATG7-dependent autophagy via SIRT1), Curcumin (Aoki 2007 Mol Pharmacol — autophagy in malignant glioma cells; transferable to senescent-cell clearance), NAC (replenishes GSH, supports proteasomal cysteine-redox balance; Sies 1999), and indirect support via the AMPK-tilting effects of α-lipoic acid and the NAD+ precursors.

Hallmark 11 — Chronic inflammation / inflammaging

Franceschi 2000 and the López-Otín 2023 update placed inflammaging as a hallmark in its own right. Mechanistic axis: NF-κB activation by TNFα / IL-1β / mtDNA-damage-associated patterns → upregulation of pro-inflammatory cytokines → tissue dysfunction. Coverage: Curcumin directly inhibits NF-κB nuclear translocation (Singh 1995 J Biol Chem; Aggarwal 2007), Resveratrol suppresses NF-κB (Manna 2000), Astaxanthin suppresses NF-κB and the p38/MAPK cascade in macrophage models (Park 2010 Mar Drugs), Pterostilbene mirrors resveratrol's NF-κB effect (McCormack 2013), Alpha-Lipoic Acid suppresses TNFα-induced NF-κB activation (Suzuki 1992 Free Radic Res Commun), and NAC is the canonical NF-κB-inhibiting redox tool (Schreck 1991 EMBO J).

Hallmark 1 — Deregulated nutrient sensing

The nutrient-sensing pathways (AMPK, mTOR, sirtuins, IGF-1) overlap with the antioxidant network at multiple nodes. Resveratrol is a substrate-specific SIRT1 activator (Hubbard 2013 Science) and an indirect AMPK activator via PDE4 inhibition (Park 2012 Cell). Pterostilbene mirrors the SIRT1 effect with longer plasma half-life. Alpha-Lipoic Acid activates AMPK in skeletal muscle (Lee 2005 Diabetes). The NAD+ precursors (Liposomal NAD+, NAD+ 5-in-1) raise the substrate ceiling for both SIRT1 and SIRT3. NAC raises GSH and indirectly supports the FOXO transcription-factor axis (Salih 2008 Curr Opin Cell Biol). See the Metabolic collection for the deeper nutrient-sensing treatment.

The Packer network — 4 compartments, 11 SKUs, primary references

Per-SKU evidence — Curcumin 1000mg + BioPerine

Active: 1,000 mg curcuminoids (≥95% by HPLC) + 5 mg BioPerine (95% piperine from Piper nigrum). Mechanism: three concurrent actions — direct ROS scavenging via the β-diketone moiety (Priyadarsini 2014), NF-κB inhibition by blocking IκBα phosphorylation and p65 nuclear translocation (Singh 1995; Aggarwal 2007), and Nrf2-Keap1 activation via Cys-151 modification on Keap1, inducing HMOX1 / NQO1 / GCLC (Balogun 2003). Why piperine: oral curcumin is poorly bioavailable — Shoba 1998 (Planta Medica) showed 5 mg piperine raises systemic curcumin AUC ~20× by inhibiting hepatic glucuronidation. Trial anchors: Sahebkar 2014 (Phytother Res) meta-analysis of 6 RCTs — curcumin reduced circulating CRP by 6.4 mg/L vs placebo; Hewlings 2017 (Foods) clinical review; Daily 2016 (J Med Food) osteoarthritis-pain meta-analysis (8 RCTs) — equivalent to NSAIDs at 12 weeks. Stacking: with omega-3 EPA/DHA, quercetin, Resveratrol/Pterostilbene (Nrf2 + SIRT1 dual). Cautions: warfarin interaction at high doses (CYP2C9 + mild platelet antagonist); pause 1 week pre-surgery. Time-to-effect: 4–6 weeks for hsCRP. Dose: 1 capsule daily with a fat-containing meal.

Per-SKU evidence — Resveratrol 600mg

Active: 600 mg trans-resveratrol (≥98% by HPLC; cis-resveratrol <2%, emodin <0.1%). Mechanism: Resveratrol is a substrate-specific SIRT1 activator — the 2010 controversy (Pacholec 2010, fluorescent-tag-artifact claim) was resolved by Hubbard 2013 (Science) which showed resveratrol activates SIRT1 against substrates with hydrophobic residues at the +1 position (FOXO3, p53, PGC-1α) but not against Pacholec's artificial Flamel substrate. Secondary: indirect AMPK activation via PDE4 inhibition (Park 2012 Cell) → cAMP → EPAC1 → Ca²⁺ → CamKKβ → AMPK. Tertiary: Nrf2-Keap1 (Kulkarni 2015) and NF-κB suppression (Manna 2000). Trial anchors: Howitz 2003 (Nature); Hubbard 2013 (Science); Timmers 2011 (Cell Metab) 30-day 150mg/d in obese men — ¹H-MRS liver-fat reduction, mitochondrial-density increase, blood-pressure reduction, CR-mimetic transcriptional signature. Why 600 mg: 150–500 mg/d covers most clinical trials; 600 mg approaches the AMPK/SIRT1 dose-response plateau with safety margin. Stacking: Pterostilbene (longer half-life), NAD+ precursors (SIRT1 substrate ceiling), Curcumin (Nrf2 dual), Berberine (parallel AMPK). Cautions: CYP3A4 inhibition at high doses — pause if on warfarin / tacrolimus; pause 1 week pre-surgery. Dose: 1 capsule daily with breakfast.

Per-SKU evidence — Pterostilbene 100mg

Active: 100 mg trans-pterostilbene (≥97% by HPLC). What it is: the 3,5-dimethoxy form of resveratrol — the same stilbene skeleton with two methyl groups added, making it markedly more lipid-soluble and bioavailable. Mechanism: retains resveratrol's SIRT1 activation (Park 2017 J Med Food review) and Nrf2 induction, but with very different PK. Why 100 mg: Riche 2014 (Funct Foods Health Dis) 12-week safety trial used 100 mg/d — no adverse signals; McCormack 2013 documents 50–250 mg/d as the clinical range. Pharmacokinetics: Kapetanovic 2011 (Cancer Chemother Pharmacol) — plasma half-life ~105 min vs ~14 min for resveratrol; oral bioavailability ~80% vs ~20%. The lipid-solubility from methylation gives better tissue penetration. Stacking: can substitute for Resveratrol when longer half-life is preferred, or stack alongside; pairs with NAD+ precursors as substrate. Cautions: as with resveratrol — mild CYP inhibition at high doses; observe with anticoagulants. Dose: 1 capsule daily with food.

Per-SKU evidence — Alpha-Lipoic Acid 600mg

Active: 600 mg α-lipoic acid (R/S-racemic; the same form used in NATHAN-1 and SYDNEY-2). Mechanism: ALA is unique for two reasons. First, the lipoate / dihydrolipoate redox couple (-0.32 V) directly reduces GSH, ascorbate, and α-tocopherol — Packer 1995 (Free Radic Biol Med) called it the "universal antioxidant" because it is active in both aqueous and lipid phases. Second, ALA is the prosthetic group of pyruvate dehydrogenase (PDH) and α-ketoglutarate dehydrogenase (KGDH) — Reed 2001 — making it a structural cofactor of the mitochondrial-matrix ATP-flux. Trial anchors: Ziegler 2011 NATHAN-1 (Diabetes Care) — 460-patient 4-year RCT in diabetic peripheral neuropathy, oral 600 mg/d, NIS-LL endpoint; Ametov 2003 SYDNEY-2 — 181-patient 5-week dose-escalation 600/1,200/1,800 mg/d, plateau at 600 mg; Hagen 2002 (FASEB J) — old-rat ALA + acetyl-L-carnitine restoration of mitochondrial function. Why 600 mg: SYDNEY-2 dose-response curve flattens at 600 mg. Stacking: CoQ10 (mitochondrial pair), Berberine (AMPK + glucose pair), NAC (GSH cycle), Acetyl-L-Carnitine. Cautions: may transiently lower fasting glucose — monitor in insulin/sulfonylurea users. Dose: 1 capsule once daily, ideally fasted (food reduces absorption ~30%).

Per-SKU evidence — Astaxanthin 12mg natural Haematococcus

Active: 12 mg astaxanthin from natural Haematococcus pluvialis microalgae (the highest-concentration natural source — wild salmon and krill bioaccumulate it from Haematococcus-eating zooplankton). Natural source matters: Beutner 2001 documents the all-trans 3S,3'S stereochemistry of natural astaxanthin versus synthetic Phaffia mixed stereoisomers. Mechanism: astaxanthin has hydroxyl groups on both ends and a polyene chain in the middle — a polar-nonpolar-polar (PNP) architecture. Goto 2001 (Biochim Biophys Acta) showed astaxanthin spans the lipid bilayer with polar ends at both aqueous interfaces, intercepting radicals at both leaflets and at the membrane core simultaneously. Vitamin E only sits at the polar interface; β-carotene only in the membrane core; astaxanthin does both. Trial anchors: Tominaga 2012 (Acta Biochim Pol) — 12-week 12 mg/d in healthy women, corneocyte-water + skin-elasticity endpoints; Hashimoto 2014 — macular pigment optical density; Yoshida 2010 — HDL increase + triglyceride decrease at 12 mg/d. Stacking: Liposomal Vitamin C (regenerates astaxanthin radical cation), CoQ10 (parallel membrane antioxidant), Multi Collagen Complex (skin-elasticity stack). Cautions: not a pro-oxidant at any tested concentration (Beutner 2001) — distinct from β-carotene's ATBC behavior. Dose: 1 softgel daily with a fat-containing meal.

Per-SKU evidence — CoQ10 400mg

Active: 400 mg coenzyme Q10 (ubiquinone form). Mechanism: CoQ10 is the lipid-soluble electron carrier between Complex I/II and Complex III in the mitochondrial inner membrane (Mitchell 1979 Nobel chemiosmotic mechanism; Crane 2001 FEBS Lett). It is also a direct membrane antioxidant in the ubiquinol (CoQ10H₂) form — protecting membrane lipids and LDL particles from peroxidation. Trial anchors: Mortensen 2014 Q-Symbio (JACC Heart Fail) — 420-patient 2-year RCT of 300 mg/d CoQ10 in NYHA III/IV chronic heart failure, primary endpoint major-adverse-cardiovascular-event; CoQ10 reduced MACE 43%; all-cause mortality reduced 42% (HR 0.58, p=0.04). Caso 2007 (Am J Cardiol) — 100 mg/d CoQ10 in statin myopathy patients, CK reduction and pain reduction. Olson 1989 mtDNA-encoded ubiquinone biosynthesis. Singh 1998 (Cardiovasc Drugs Ther) — CoQ10 in MI patients showed reduced angina recurrence. Why 400 mg: 100–300 mg covers most cardiac trials; 400 mg is the upper-clinical-zone for higher-mitochondrial-load contexts (statin-myopathy, post-MI, advanced age with Mitsui 2017 ubiquinone-decline). Endogenous CoQ10 biosynthesis declines with age (Kalén 1989 Lipids); supplementation restores plasma levels. Stacking: with statins (mandatory consideration if on a statin — endogenous biosynthesis is reduced by HMG-CoA-reductase inhibition); with α-lipoic acid (mitochondrial pair); with NAD+ precursors (electron-transport ↔ NAD+/NADH cycle). Cautions: mild warfarin interaction (CoQ10 has structural similarity to vitamin K); INR monitoring if both prescribed. Dose protocol: 1 capsule daily with breakfast — fat-soluble; preferred form is ubiquinone for stability and trial-matched data, ubiquinol if absorption issues.

Per-SKU evidence — Glutathione 500mg enteric-coated reduced GSH

Active: 500 mg reduced L-glutathione (γ-glutamyl-cysteinyl-glycine; GSH form, not the oxidized GSSG dimer), in enteric-coated capsules to bypass gastric γ-glutamyl-transpeptidase cleavage. Mechanism: Glutathione is the master endogenous antioxidant — present at 1–10 mM concentration in most cells (the highest cytosolic concentration of any non-protein thiol). It detoxifies H₂O₂ via glutathione peroxidase (Forman 2009 Mol Aspects Med), conjugates electrophilic xenobiotics via glutathione S-transferase (Hayes 2005 Annu Rev Pharmacol Toxicol), and recycles ascorbate and α-tocopherol radicals at the membrane interface. The bioavailability problem: Witschi 1992 (Eur J Clin Pharmacol) showed plain oral GSH has poor systemic delivery — γ-glutamyl-transpeptidase in the gut wall cleaves it. Enteric coating dissolves in the small intestine, allowing direct GSH absorption + systemic delivery. Trial anchors: Richie 2015 (Eur J Nutr) — 54-subject 6-month RCT of oral reduced GSH 250 or 1000 mg/d, showed dose-dependent increase in RBC, plasma, and lymphocyte GSH plus reduction in oxidative-stress markers. The 500 mg dose sits between these two arms. Park 2014 (Eur J Nutr) showed parallel skin-tone signal at 500 mg/d. Stacking: with NAC (parallel GSH precursor + direct GSH supply), with vitamin C (regenerates GSH from GSSG via thiol-disulfide exchange), with α-lipoic acid (network bridge — DHLA reduces GSSG to GSH directly). Cautions: sulfur-containing metabolites can produce mild body-odor changes at high doses; pause if scheduled for sulfur-skin-test allergy panel. Dose protocol: 1 capsule daily, fasted (so the enteric coating is the absorption gate, not gastric pH variability).

Per-SKU evidence — N-Acetyl Cysteine 600mg

Active: 600 mg N-acetyl-L-cysteine (USP / pharmacopoeia-grade — the same NAC entity used as a pharmaceutical mucolytic and paracetamol-overdose antidote). Mechanism: NAC is the rate-limiting cysteine donor for endogenous GSH synthesis. The GSH-synthesis pathway is γ-glutamyl-cysteine ligase (GCLC) + glutathione synthase (GSS); GCLC's K_m for cysteine is ~0.1 mM, well above intracellular cysteine concentrations under stress — so cysteine availability is the rate-limiting step (Lu 2013 Mol Aspects Med). NAC is rapidly deacetylated to L-cysteine, raising GSH-synthesis rate. NAC is also a direct mild thiol-redox antioxidant, mucolytic (cleaves mucin disulfide bridges), and a NF-κB inhibitor (Schreck 1991 EMBO J — the canonical paper). Trial anchors: Smilkstein 1988 (NEJM) — IV NAC in paracetamol overdose, the gold-standard hepatotoxicity antidote; MARCO 2014 (Chest) — chronic bronchitis prevention of exacerbations; Demedts 2005 IFIGENIA (NEJM) — exploratory data in idiopathic pulmonary fibrosis (later partly contradicted by PANTHER-IPF, so treat as exploratory not confirmed); Berk 2014 (J Affect Disord) — adjunctive NAC in bipolar depression. Why 600 mg: the MARCO chronic-bronchitis dose; the Berk depression-adjunct dose; well below the gram-level pharmaceutical mucolytic ceiling. Stacking: with Glutathione (direct GSH + precursor combo); with vitamin C; with selenium (cofactor for glutathione peroxidase — endogenous selenium status often suboptimal). Cautions: sulfur smell at high doses; PANTHER-IPF-type nuances mean we don't claim IPF benefit; can blunt exercise-induced adaptation (Ristow 2009 family of papers — pause peri-workout if optimizing exercise gains). Dose protocol: 1 capsule daily, anytime; not peri-workout if maximizing exercise adaptation.

Per-SKU evidence — Liposomal Vitamin C 1000mg

Active: 1,000 mg L-ascorbic acid encapsulated in sunflower-derived phosphatidylcholine liposomes. Mechanism: Vitamin C is (a) the terminal aqueous-phase free-radical scavenger in the Packer network, regenerating α-tocopherol radicals at the membrane interface; (b) the prolyl-hydroxylase and lysyl-hydroxylase cofactor in collagen biosynthesis (Carr 2017 Nutrients; Pinnell 2003 Yale J Biol Med); (c) a cofactor for dopamine-β-hydroxylase, peptidyl-glycine α-amidating monooxygenase, and the DNA-demethylating TET dioxygenases (Yin 2013 J Am Chem Soc). The bioavailability problem: oral ascorbic acid has saturable intestinal SVCT1 transport — Padayatty 2004 (Ann Intern Med) showed plasma plateau ~80 µM at 200 mg/d single dose; doses above 1 g/d return diminishing plasma yield. Liposomal solution: phospholipid encapsulation enters via paracellular and lipid-soluble routes, effectively bypassing the SVCT1 saturation. Davis 2016 (Nutr Metab Insights) showed liposomal ascorbic acid roughly doubled plasma AUC vs equivalent unencapsulated tablets in a small crossover trial. Hickey 2008 (J Nutr Environ Med) reported plasma vitamin C above 400 µM with multi-gram liposomal dosing. Trial anchors: Padayatty 2003 (Ann Intern Med) review of vitamin C pharmacokinetics; Davis 2016 liposomal plasma AUC; Carr 2017 collagen role review; Hemilä 2013 Cochrane vitamin C and the common cold. Stacking: with Multi Collagen Complex (procollagen substrate + cofactor); with Astaxanthin (regenerates astaxanthin); with reduced GSH (thiol-disulfide cycling); with α-lipoic acid (network bridge). Cautions: at gram-doses can cause loose stools (osmotic; titrate to bowel-tolerance); kidney-stone history is the standard contraindication for chronic high-dose vitamin C. Dose protocol: 1 sachet/capsule daily, anytime — liposomal absorption is less meal-dependent than tablet absorption.

Per-SKU evidence — Liposomal NAD+ Ultimate 1000mg + NAD+ 5-in-1 Complete

What these are: two combo formulas that pair NAD+ precursor (β-NMN) with the cofactor stack that supports NAD+/sirtuin biology. Liposomal NAD+ Ultimate 1000mg: 10-active phospholipid-encapsulated formula combining β-NMN with CoQ10, riboflavin/FAD, niacinamide, B-complex, and lipid-membrane-targeting cofactors. NAD+ 5-in-1 Complete: NMN + CoQ10 + B-Complex + antioxidants + skin-targeted cofactors in a single capsule. Mechanism: NAD+ is the central oxidoreductase cofactor — the substrate of the sirtuin family (SIRT1 nuclear, SIRT3 mitochondrial), the PARP DNA-damage-response enzymes, and the CD38 ectoenzyme. NAD+ levels decline ~50% by age 50 (Massudi 2012 PLoS ONE; Camacho-Pereira 2016 Cell Metab) — the decline tracks with mitochondrial dysfunction, sirtuin activity drop, and senescence accumulation. β-NMN raises tissue NAD+ via the NMNAT1/2/3 → NAD+ pathway; CoQ10 supports electron-transport that consumes NADH back to NAD+; the B-complex provides cofactors for one-carbon metabolism and amino-acid catabolism. Trial anchors (NAD+ precursors): Yoshino 2021 (Science) — 250 mg/d β-NMN in postmenopausal women with prediabetes raised muscle insulin sensitivity; Pencina 2023 — pharmacokinetic + safety; Igarashi 2022 (npj Aging) — 1,250 mg/d in older men dose-escalation safety; Liao 2021 — 600/900/1,200 mg/d aerobic-capacity signal; Yi 2023 — 900 mg/d 60-day biological-age signal. Trial anchors (CoQ10): Mortensen 2014 Q-Symbio (NYHA III/IV mortality reduction). Why these formulas: covers SIRT1 + SIRT3 substrate ceiling, mitochondrial electron transport, and the methyl-buffer / B-complex needs of higher NAD+ flux. Stacking: see the NAD+ Family collection for in-depth NAD+ guidance; pairs with Resveratrol/Pterostilbene for SIRT1 activation, with Berberine for AMPK route, with TMG / Methylated B-complex if methyl-buffer concerns exist. Dose protocol: 1 capsule daily with breakfast.

Stacking protocols — 5 reference protocols

Beginner stack — start simple, build redundancy

Curcumin 1000mg + BioPerine + Astaxanthin 12mg + ALA 600mg. Three SKUs covering Nrf2 / NF-κB (curcumin), membrane (astaxanthin), and the universal-network bridge (ALA). 4-week orientation, then expand based on goals.

Beauty & skin antioxidant stack

Astaxanthin 12mg + Liposomal Vitamin C 1000mg + Multi Collagen Complex (Collagen collection) + Glutathione 500mg. Anchored in Tominaga 2012 corneocyte-water + Pinnell 2003 collagen-cofactor + Park 2014 skin-tone evidence. 8–12 weeks for elasticity / hydration endpoints.

Cardiovascular antioxidant stack

CoQ10 400mg + Curcumin 1000mg + ALA 600mg + (statin-myopathy: add Liposomal Vitamin C 1000mg). Anchored in Q-Symbio 2014 + Sahebkar 2014 CRP + Caso 2007 CK reduction. 12–24 weeks for cardiac-output endpoints.

Mitochondrial-renewal stack

ALA 600mg + CoQ10 400mg + Astaxanthin 12mg + Liposomal NAD+ Ultimate 1000mg or NAD+ 5-in-1 Complete + Resveratrol 600mg. Covers PDH/KGDH cofactor (ALA), inner-membrane electron transport (CoQ10), membrane-spanning radical termination (astaxanthin), NAD+ substrate ceiling for SIRT1/SIRT3 (NAD+ formula), and substrate-specific SIRT1 activation (resveratrol). The López-Otín Hallmark 4 stack. 8–12 weeks.

Comprehensive stack — everything in this collection

Curcumin 1000mg + BioPerine + Resveratrol 600mg + Pterostilbene 100mg (or sub for resveratrol) + ALA 600mg + Astaxanthin 12mg + CoQ10 400mg + NAC 600mg + Glutathione 500mg + Liposomal Vitamin C 1000mg + Liposomal NAD+ Ultimate 1000mg or NAD+ 5-in-1 Complete. The full Packer-network coverage. Take with breakfast (fat-soluble: astaxanthin, CoQ10, curcumin, resveratrol, pterostilbene); fasted morning option (ALA); evening option (GSH, NAC). Time-to-effect ranges from 1–2 weeks (Nrf2 transcriptional markers) to 12+ weeks (cardiac, mitochondrial, skin endpoints).

Time-to-effect timeline (week-by-week)

What to avoid — the 6 antioxidant mistakes

1. Mega-dosing single antioxidants. ATBC 1994, CARET 1996, SELECT 2011 — the three landmark "antioxidant supplementation harm" trials all share one design feature: a single isolated antioxidant given at very high dose. Network coverage avoids this. We cap each SKU at the trial-anchored dose.
2. Synthetic vitamin E mega-doses. The SELECT 2011 prostate-cancer signal was specifically with synthetic α-tocopherol acetate at 400 IU/d. We do not recommend isolated high-dose synthetic vitamin E.
3. β-Carotene in smokers / asbestos-exposed. ATBC and CARET both showed harm in this specific population — β-carotene auto-oxidizes in high-O₂-tension lung tissue. We do not stock isolated β-carotene; astaxanthin is a different molecule with different chemistry and a clean safety record (Beutner 2001).
4. Antioxidants peri-chemotherapy. The interaction debate is unresolved; standard oncology practice is to pause antioxidants for 48 hours before / during / 48 hours after infusion-chemotherapy and radiation. We surface this in the per-SKU detail and the FAQ.
5. Antioxidants peri-workout if optimizing exercise adaptation. Ristow 2009 (PNAS) and downstream papers show vitamin C 1000mg + vitamin E 400 IU peri-workout blunts insulin sensitization and PGC-1α induction. If exercise adaptation is the priority, time antioxidants away from the workout window.
6. "ORAC score" shopping. The USDA officially withdrew its ORAC database in 2012 because in vitro radical-scavenging capacity correlated poorly with in vivo function. ORAC is not a meaningful selection criterion.

Frequently asked antioxidant questions

What is the difference between an antioxidant and a Nrf2 activator?

An antioxidant directly donates an electron to a radical species, neutralizing it (vitamin C, vitamin E, GSH, astaxanthin). A Nrf2 activator transcriptionally upregulates the genes that produce endogenous antioxidant enzymes (HMOX1, NQO1, GCLC) — raising the baseline antioxidant capacity. Curcumin, resveratrol, pterostilbene, and α-lipoic acid all have Nrf2 activity. The modern stack uses both — direct scavenging plus Nrf2 induction — because they hit different timescales (hours vs days) and different parts of the network.

Should I take antioxidants with my workouts?

Probably not the high-dose ones. Ristow 2009 (PNAS) showed vitamin C 1000mg + vitamin E 400 IU peri-workout blunts insulin sensitization and PGC-1α induction. The exercise-induced ROS pulse is the signal for mitochondrial biogenesis (Sies 2017 oxidative-eustress framing). If exercise adaptation is your priority, take antioxidants 4–6 hours away from the workout. If hsCRP / chronic-inflammation reduction is your priority, the timing matters less.

Is "ORAC score" a reliable measure of antioxidant strength?

No. The USDA officially withdrew its ORAC database in 2012, citing "no evidence that the antioxidant levels in foods translate into specific health benefits in humans." ORAC measures in vitro free-radical scavenging in a test-tube AAPH assay — it does not capture absorption, cellular uptake, Nrf2 induction, NF-κB suppression, mitochondrial localization, or any other in vivo determinant of biological effect. Ignore ORAC; pick by mechanism and trial.

Can you take too many antioxidants?

Yes, in two ways. First, single-compound mega-dosing was harmful in ATBC, CARET, and SELECT — network coverage at trial-anchored doses avoids this. Second, peri-workout antioxidants blunt exercise adaptation. The collection is engineered to keep you in the "network coverage at trial-anchored dose" zone — not the "mega-dose one thing" zone.

Are antioxidants better from food or supplements?

Both. Polyphenol-rich foods (berries, dark leafy greens, green tea, dark chocolate, cruciferous vegetables) deliver low-to-moderate doses of dozens of compounds with synergy and matrix-effect bioavailability. Supplements deliver higher trial-anchored doses of specific compounds with verified purity and dose. The longevity literature mostly used supplement doses (Timmers 2011 used 150 mg/d resveratrol — equivalent to ~75 bottles of red wine per day; not achievable from food). Use both.

Do antioxidants interact with chemotherapy?

The interaction is unresolved. Some chemotherapy mechanisms (anthracyclines, radiation) work via ROS generation, and antioxidants could blunt their efficacy — though clinical-trial evidence is inconsistent. Standard oncology practice is to pause all antioxidants for 48 hours before, during, and 48 hours after infusion-chemotherapy and radiation. This is the policy we recommend. Resume after the washout window per oncologist guidance.

How long until I notice anything?

Depends on the endpoint. Subjective energy / fatigue: 1–2 weeks. Skin elasticity / hydration: 8–12 weeks. hsCRP: 4–8 weeks. HbA1c: 12 weeks. Cardiac-output endpoints: 12–24 weeks. Biological-age (epigenetic-clock) signal: 24+ weeks. See the time-to-effect timeline above for the full table.

Do I need to cycle antioxidants?

No, generally. Cycling makes sense for compounds with receptor downregulation (e.g., caffeine), tachyphylaxis, or accumulating risk profiles. Antioxidant supplementation at trial-anchored doses does not show those features. The exception is peri-workout (cycle out of the workout window) and peri-chemotherapy (mandatory pause).

Is it safe to take all of these together?

For most healthy adults, yes — the comprehensive stack uses 11 SKUs at individually trial-anchored doses, and the Packer-network framing is specifically about network redundancy at moderate doses, not single-compound mega-dosing. Always check with your physician if you are on warfarin, anticoagulants, immunosuppressants (tacrolimus), narrow-therapeutic-index drugs, or scheduled for surgery within 2 weeks.

Selected references (37 citations)

1. Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol. 1956;11(3):298-300.
2. Harman D. The biologic clock: the mitochondria? J Am Geriatr Soc. 1972;20(4):145-147.
3. Cadenas E, Davies KJ. Mitochondrial free radical generation, oxidative stress, and aging. Free Radic Biol Med. 2000;29(3-4):222-230.
4. López-Otín C, et al. The hallmarks of aging. Cell. 2013;153(6):1194-1217.
5. López-Otín C, et al. Hallmarks of aging: an expanding universe. Cell. 2023;186(2):243-278.
6. Packer L, Witt EH, Tritschler HJ. Alpha-lipoic acid as a biological antioxidant. Free Radic Biol Med. 1995;19(2):227-250.
7. Itoh K, et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun. 1997;236(2):313-322.
8. Sies H. Hydrogen peroxide as a central redox signaling molecule in physiological oxidative stress: oxidative eustress. Redox Biol. 2017;11:613-619.
9. Ristow M, et al. Antioxidants prevent health-promoting effects of physical exercise in humans. PNAS. 2009;106(21):8665-8670.
10. Tonelli C, Chio IIC, Tuveson DA. Transcriptional regulation by Nrf2. Antioxid Redox Signal. 2018;29(17):1727-1745.
11. Balogun E, et al. Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element. Biochem J. 2003;371(Pt 3):887-895.
12. Aggarwal BB, Shishodia S. Suppression of the nuclear factor-kappaB activation pathway by spice-derived phytochemicals. Adv Exp Med Biol. 2007;595:425-451.
13. Sahebkar A. Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Phytother Res. 2014;28(5):633-642.
14. Shoba G, et al. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998;64(4):353-356.
15. Howitz KT, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003;425(6954):191-196.
16. Hubbard BP, et al. Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science. 2013;339(6124):1216-1219.
17. Timmers S, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011;14(5):612-622.
18. Park SJ, et al. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell. 2012;148(3):421-433.
19. Kapetanovic IM, et al. Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother Pharmacol. 2011;68(3):593-601.
20. McCormack D, McFadden D. A review of pterostilbene antioxidant activity and disease modification. Oxid Med Cell Longev. 2013;2013:575482.
21. Ziegler D, et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care. 2011;34(9):2054-2060.
22. Ametov AS, et al. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care. 2003;26(3):770-776.
23. Hagen TM, et al. Feeding acetyl-L-carnitine and lipoic acid to old rats significantly improves metabolic function while decreasing oxidative stress. FASEB J. 2002;16(14):1779-1786.
24. Reed LJ. A trail of research from lipoic acid to alpha-keto acid dehydrogenase complexes. J Biol Chem. 2001;276(42):38329-38336.
25. Goto S, et al. Efficient radical trapping at the surface and inside the phospholipid membrane is responsible for highly potent antioxidative activity of the carotenoid astaxanthin. Biochim Biophys Acta. 2001;1512(2):251-258.
26. Beutner S, et al. Quantitative assessment of antioxidant properties of natural colorants and phytochemicals: carotenoids, flavonoids, phenols and indigoids. Mol Aspects Med. 2001;22(4-5):245-292.
27. Tominaga K, et al. Cosmetic benefits of astaxanthin on humans subjects. Acta Biochim Pol. 2012;59(1):43-47.
28. Mortensen SA, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO. JACC Heart Fail. 2014;2(6):641-649.
29. Caso G, et al. Effect of coenzyme Q10 on myopathic symptoms in patients treated with statins. Am J Cardiol. 2007;99(10):1409-1412.
30. Richie JP Jr, et al. Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. Eur J Nutr. 2015;54(2):251-263.
31. Witschi A, et al. The systemic availability of oral glutathione. Eur J Clin Pharmacol. 1992;43(6):667-669.
32. Smilkstein MJ, et al. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. NEJM. 1988;319(24):1557-1562.
33. Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor. EMBO J. 1991;10(8):2247-2258.
34. Padayatty SJ, et al. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med. 2004;140(7):533-537.
35. Davis JL, et al. Liposomal-encapsulated ascorbic acid: influence on vitamin C bioavailability and capacity to protect against ischemia-reperfusion injury. Nutr Metab Insights. 2016;9:25-30.
36. Carr AC, Maggini S. Vitamin C and immune function. Nutrients. 2017;9(11):1211.
37. Yoshino M, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229.

Disclaimer

These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Consult your physician before starting any supplement program — especially if you take warfarin, anticoagulants, immunosuppressants, are pregnant, are nursing, or are scheduled for surgery within 2 weeks. Antioxidant supplementation should be paused for 48 hours before, during, and 48 hours after infusion-chemotherapy or radiation per standard oncology practice. Individual results vary; the trial-anchored time-to-effect ranges in this page are population-level, not individual guarantees.